bluuebunny/crossref_metadata_2025 huggingface dataset:
Optimizing Catalyst Layer Structure with Carbon Nanofiber Additive for Better Performance of Proton Exchange Membrane Fuel Cell
Authors: Han Tianyi , Xu Liangfei , Zhao Yang , Zhang Shukai , Hu Zunyan , Li Jianqiu , Ouyang Minggao
Published: September 2023

Increasing the power density of proton exchange membrane fuel cell (PEMFC) is essential for its commercialization. Cathode catalyst layer (CCL) carbon additive is an effective method that can improve membrane electrode assembly (MEA) performance under high current density. In this work, carbon nanofiber (CNF) is used as CCL additive and its mechanism is studied. The influence of CNF on the CCL structure is studied by scanning electron microscope (SEM), nitrogen adsorption method and contact angle experiment. Meanwhile, the mechanism is examined by using polarization decomposition and impedance analysis combined with the result in characterization experiments. The results show that: (1) the MEA used in this work has the best performance when adding 1 wt%. The voltage rises 74 mV (15.42%) at 2 A cm−2; (2) CNF varies the MEA performance mainly through changing the hydrophobicity of CCL, influencing the mass transport resistance and the concentration polarization. The mass transport resistance decreases 57.18% at 2 A cm−2; (3) activation polarization values have a negative linear correlation with the peak volume values of the primary pores at around 4 nm in diameter. This study provided a detailed understanding of the mechanism of CNF additive in CCL and will be helpful for improving PEMFC performance.
Efficient Removal of Paraquat Pollutants Using Magnetic Biochar Derived from Corn Husk Waste: A Sustainable Approach for Water Remediation
Authors: Damdib Sakonsupa , Siyasukh Adisak , Vanichsetakul Bhawaranchat , Phamornpiboon Phamornsiri , Thanachayanont Chanchana , Punyapalakul Patiparn , Tonanon Nattaporn
Published: September 2023

Due to the widespread production of maize, the waste created by this crop has become a serious concern. This study applied the concept of waste circulation to the production of magnetic biochar from corn husk waste to remediate paraquat-contaminated water. Magnetic biochar (MB) was produced by impregnating maize husks with iron and carbonizing the residue in a nitrogen environment. Carbonized MB at the temperature of 850°C (MB-01-850) exhibited a combination of microporous and mesoporous structures ([Formula: see text], [Formula: see text]), while biochar created only a microporous structure ([Formula: see text]). According to the findings, Fe(NO3)3 significantly affected the increase in mesopore formation after carbonization. In addition, biochar exhibits excellent magnetic responsiveness. MB-01-850 reached equilibrium within approximately 20 min in synthetic water. Batch adsorption studies showed that MB-01-850 had maximum adsorption capacities ([Formula: see text]) of 34.97 mg/g and 31.63 mg/g for synthetic and natural water, respectively. The unmodified biochar (without mesopores) had a [Formula: see text] of 4.08 mg/g. This indicates that the presence of mesopores improves the effectiveness of paraquat adsorption. Additionally, the adsorption performance of magnetic biochar exhibited no statistically significant variance when tested under natural water conditions. Furthermore, magnetic biochar demonstrates impressive regeneration capacity, allowing it to be regenerated almost entirely for a minimum of four cycles using a sodium hydroxide (NaOH) solution with a concentration equal to or greater than 0.5 M.
Intravascular Large B-Cell Lymphoma
Authors: Loukhnati Mehdi , Lahlimi Fatima Ezzahra , Tazi Illias
Published: September 2023

Intravascular large B-cell lymphoma (IVBCL) is a very rare and aggressive subtype of extranodal diffuse large B-cell lymphoma (DLBCL) involving the growth of lymphoma cells within blood vessels of all organ types. We present the case of a 55-year-old North-African man with no prior history of neoplastic disease presenting with weight loss and an isolated splenomegaly. Investigations led to the diagnosis of this disease. To the best of our knowledge, this is the first case recorded in Africa. Through this article, we discuss this case and outline the common presentation, paraclinical investigations, and treatment options of IVBCL.
Internet Addiction and Sleep Disorders among Medical Students
Authors: Kashfi Seyyed Mansour , Karami Hamed , Jafari Fatemeh , Daliri Masumeh , Yazdankhah Maryam , Kamyab Amirhossein , Khani Jeihooni Ali
Published: September 2023

Background. Considering the increasing use of the Internet in Iranian society, especially among students, and the importance of sleep quality, the present study investigated the relationship between sleep quality and Internet addiction among medical students in Shiraz. Methods. In this descriptive-analytical study, the sample included students of the Shiraz University of Medical Sciences who were selected by a multistage sampling method in 2018. Each faculty was considered to be stratified, and the samples were selected from all strata by simple random sampling. A total of 400 student questionnaires were eligible for analysis. The level of sleep disturbance was measured using the Pittsburgh Sleep Quality Index (PSQI), and Young’s Internet Addiction Test (IAT) was used to evaluate Internet addiction. Cronbach’s alpha for PSQI and IAT was 0.77 and 0.93, respectively. Results. 109 (%28.9) and 58 (%14.4) of all the people under study were at risk of Internet addiction or poor sleep quality, respectively. The highest percentage of poor sleep quality was in those who were addicted to the Internet (60%), but the lowest percentage was observed in the group without addiction (27%). In addition, there was a significant correlation between Internet addiction and subjective sleep quality (r = 0.191,

p

 = 0.05), sleep latency (r = 0.129,

p

 = 0.01), sleep duration (r = 0.119,

p

 = 0.01), habitual sleep efficiency (r = 0.186,

p

 = 0.05), sleep disturbances (r = 0.169,

p

 = 0.01), use of sleeping medication (r = 0.203,

p

 = 0.05), and daytime dysfunction (r = 0.188,

p

 = 0.05). Conclusion. These findings help national health officials and planners in Iran to design appropriate and effective interventions to improve students’ health and prevent Internet addiction.
Comparing the Trends of Vector-Borne Diseases (VBDs) before and after the COVID-19 Pandemic and Their Spatial Distribution in Southern Iran
Authors: Gheibi Zahra , Boroomand Mitra , Soltani Aboozar
Published: September 2023

Objectives. We aimed to model and predict the changes in the trend of vector-borne diseases (VBDs) before and after the COVID-19 pandemic in a high-risk area of Iran. Methods. This case-series study was conducted in Fars province, south of Iran, between April 2016 and July 2021. All referred cases of VBDs were considered during the five years to investigate the effect of the lockdown on the epidemiological profile of these diseases. We used time-series autoregressive integrated moving average (ARIMA) and seasonal ARIMA (SARIMA) models. Results. Pediculosis incidence trend was rising with a peak of 1,146 per 100,000 in 2018, followed by a dramatic decrease reached to the minimum amount of 157.8 per 100,000 in 2021. In contrast, malaria and scabies had a smooth decreasing trend ranging from 2.2 per 100,000 and 7.3 per 100,000 in 2016 to a minimum of 0.2 per 100,000 in 2021, respectively. Likewise, leishmaniasis had a falling trend, with a maximum rate of 82.9 per 100,000 in 2016 to the lowest rate of 9.4 per 100,000 in 2021. However, the difference between observed and expected values revealed that the consequences of the COVID-19 pandemic had increased the number of leishmaniasis cases. Conclusion. Tropical regions of Iran, including Fars province, are the favorite destinations for travelers. During COVID-19 outbreaks, some reasons, such as quarantine, movement restrictions, and social distancing, reduced human-vector contact and finally led to the reduction of VBDs in this area.
Analysis of Fouling Pattern of Tunnel Drainage Pipe in Karst Areas
Authors: Lv Jianbing , Wu Hao , Li Jia , Wan Xiaodong , Fu Helin
Published: September 2023

As the groundwater in karst areas is rich in calcium ions, when the groundwater flows out of the tunnel drainage pipe, calcium carbonate crystals will be precipitated and then adhere to the pipe wall, which will easily cause chemical blockage in the drainage pipe wall, thus affecting the drainage efficiency and leading to the increase of water pressure outside the tunnel lining, affecting the safety and stability of the structure. Therefore, the blockage of calcium carbonate crystals in tunnel drains is one of the most important problems for the safe and normal operation of tunnels. In order to quantify and qualify the process of crystalline blockage in the drainage system of tunnels in karst areas, this paper constructs a numerical model with coupled multiphysical fields of the flow field and particle concentration field and also combines data from indoor tests to compare and verify the simulation results and analyze the time-varying law of crystalline solids deposited on the pipe wall. In this paper, we consider the force situation of crystalline solids in the pipe by water flow, analyze the related theories, comprehensively study the migration and deposition law of crystalline particles in the drainage pipe, and establish a numerical simulation model of the pipe crystallization rate considering temperature, flow velocity and concentration of sediment particles based on ANSYS FLUENT software, and refine and analyze several parameters in the model, so that it can provide a theoretical analysis framework for the tunnel drainage pipe blockage in karst areas by providing a theoretical analysis framework.
Supplementary Table 1 from ESRRB Inhibits the TGFβ Signaling Pathway to Drive Cell Proliferation in Cervical Cancer
Authors: Li Qin-Shu , Zheng Peng-Sheng
Published: September 2023

Semi‒quantitative statistical table of ESRRB staining in NC, HSIL and CC
Figure S1 from ESRRB Inhibits the TGFβ Signaling Pathway to Drive Cell Proliferation in Cervical Cancer
Authors: Li Qin-Shu , Zheng Peng-Sheng
Published: September 2023

Fig. S1 describes the pan-cancer analysis of ESRRB; cell line validation; tumor-free growth period of transplanted tumors in vivo; and apoptosis analysis.
Supplementary Data from Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer
Authors: Marín Arnaldo , Mamun Abdullah Al , Patel Hima , Akamatsu Hiroaki , Ye Dan , Sudhan Dhivya R. , Eli Lisa , Marcelain Katherine , Brown Benjamin P. , Meiler Jens , Arteaga Carlos L. , Hanker Ariella B.
Published: September 2023

Supplementary Materials and Methods, Key Resource Table, and Supplementary Figures 1-8
Table S3 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Authors: Wu Hong , Leng Xuefeng , Liu Qianshi , Mao Tianqin , Jiang Tao , Liu Yiqiang , Li Feifei , Cao Chenhui , Fan Jun , Chen Liang , Chen Yaqi , Yao Quan , Lu Shun , Liang Renchuan , Hu Lanlin , Liu Mingxin , Wan Yejian , Li Zhaoshen , Peng Jun , Luo Qiyu , Zhou Hang , Yin Jun , Xu Ke , Lan Mei , Peng Xinhao , Lan Haitao , Li Gang , Han Yongtao , Zhang Xia , Xiao Zhi-Xiong Jim , Lang Jinyi , Wang Guihua , Xu Chuan
Published: September 2023

Table S3 shows clinical characteristics of feces providers for fecal microbiota transplantation.
Table S2 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Authors: Wu Hong , Leng Xuefeng , Liu Qianshi , Mao Tianqin , Jiang Tao , Liu Yiqiang , Li Feifei , Cao Chenhui , Fan Jun , Chen Liang , Chen Yaqi , Yao Quan , Lu Shun , Liang Renchuan , Hu Lanlin , Liu Mingxin , Wan Yejian , Li Zhaoshen , Peng Jun , Luo Qiyu , Zhou Hang , Yin Jun , Xu Ke , Lan Mei , Peng Xinhao , Lan Haitao , Li Gang , Han Yongtao , Zhang Xia , Xiao Zhi-Xiong Jim , Lang Jinyi , Wang Guihua , Xu Chuan
Published: September 2023

Table S2 shows clinical characteristics of patients with esophageal squamous cell carcinoma (ESCC) who underwent NACI1 treatment.
Table S1 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Authors: Wu Hong , Leng Xuefeng , Liu Qianshi , Mao Tianqin , Jiang Tao , Liu Yiqiang , Li Feifei , Cao Chenhui , Fan Jun , Chen Liang , Chen Yaqi , Yao Quan , Lu Shun , Liang Renchuan , Hu Lanlin , Liu Mingxin , Wan Yejian , Li Zhaoshen , Peng Jun , Luo Qiyu , Zhou Hang , Yin Jun , Xu Ke , Lan Mei , Peng Xinhao , Lan Haitao , Li Gang , Han Yongtao , Zhang Xia , Xiao Zhi-Xiong Jim , Lang Jinyi , Wang Guihua , Xu Chuan
Published: September 2023

Table S1 shows clinical characteristics of esophageal squamous cell carcinoma (ESCC) patients who underwent upfront surgery.
Figure S8 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Authors: Wu Hong , Leng Xuefeng , Liu Qianshi , Mao Tianqin , Jiang Tao , Liu Yiqiang , Li Feifei , Cao Chenhui , Fan Jun , Chen Liang , Chen Yaqi , Yao Quan , Lu Shun , Liang Renchuan , Hu Lanlin , Liu Mingxin , Wan Yejian , Li Zhaoshen , Peng Jun , Luo Qiyu , Zhou Hang , Yin Jun , Xu Ke , Lan Mei , Peng Xinhao , Lan Haitao , Li Gang , Han Yongtao , Zhang Xia , Xiao Zhi-Xiong Jim , Lang Jinyi , Wang Guihua , Xu Chuan
Published: September 2023

Figure S8 shows intra-tumoral bacterial contents were stable during tumor growth.
Figure S7 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Authors: Wu Hong , Leng Xuefeng , Liu Qianshi , Mao Tianqin , Jiang Tao , Liu Yiqiang , Li Feifei , Cao Chenhui , Fan Jun , Chen Liang , Chen Yaqi , Yao Quan , Lu Shun , Liang Renchuan , Hu Lanlin , Liu Mingxin , Wan Yejian , Li Zhaoshen , Peng Jun , Luo Qiyu , Zhou Hang , Yin Jun , Xu Ke , Lan Mei , Peng Xinhao , Lan Haitao , Li Gang , Han Yongtao , Zhang Xia , Xiao Zhi-Xiong Jim , Lang Jinyi , Wang Guihua , Xu Chuan
Published: September 2023

Figure S7 shows fecal microbial transplantation (FMT) influenced the immune microenvironment of subcutaneous xenograft tumor tissues.
Figure S4 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Authors: Wu Hong , Leng Xuefeng , Liu Qianshi , Mao Tianqin , Jiang Tao , Liu Yiqiang , Li Feifei , Cao Chenhui , Fan Jun , Chen Liang , Chen Yaqi , Yao Quan , Lu Shun , Liang Renchuan , Hu Lanlin , Liu Mingxin , Wan Yejian , Li Zhaoshen , Peng Jun , Luo Qiyu , Zhou Hang , Yin Jun , Xu Ke , Lan Mei , Peng Xinhao , Lan Haitao , Li Gang , Han Yongtao , Zhang Xia , Xiao Zhi-Xiong Jim , Lang Jinyi , Wang Guihua , Xu Chuan
Published: September 2023

Figure S4 shows intra-tumoral bacteria identified in patients with ESCC.
Figure S3 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Authors: Wu Hong , Leng Xuefeng , Liu Qianshi , Mao Tianqin , Jiang Tao , Liu Yiqiang , Li Feifei , Cao Chenhui , Fan Jun , Chen Liang , Chen Yaqi , Yao Quan , Lu Shun , Liang Renchuan , Hu Lanlin , Liu Mingxin , Wan Yejian , Li Zhaoshen , Peng Jun , Luo Qiyu , Zhou Hang , Yin Jun , Xu Ke , Lan Mei , Peng Xinhao , Lan Haitao , Li Gang , Han Yongtao , Zhang Xia , Xiao Zhi-Xiong Jim , Lang Jinyi , Wang Guihua , Xu Chuan
Published: September 2023

Figure S3 shows bacterial components differed between the NACI responders and non-responders of ESCC patients.
Figure S2 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Authors: Wu Hong , Leng Xuefeng , Liu Qianshi , Mao Tianqin , Jiang Tao , Liu Yiqiang , Li Feifei , Cao Chenhui , Fan Jun , Chen Liang , Chen Yaqi , Yao Quan , Lu Shun , Liang Renchuan , Hu Lanlin , Liu Mingxin , Wan Yejian , Li Zhaoshen , Peng Jun , Luo Qiyu , Zhou Hang , Yin Jun , Xu Ke , Lan Mei , Peng Xinhao , Lan Haitao , Li Gang , Han Yongtao , Zhang Xia , Xiao Zhi-Xiong Jim , Lang Jinyi , Wang Guihua , Xu Chuan
Published: September 2023

Figure S2 shows intra-tumoral microbial diversity of patients with ESCC.
Table S3 from Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
Authors: Gulay Kevin Christian Montecillo , Zhang Xinlian , Pantazopoulou Vasiliki , Patel Jay , Esparza Edgar , Pran Babu Deepa Sheik , Ogawa Satoshi , Weitz Jonathan , Ng Isabella , Mose Evangeline S. , Pu Minya , Engle Dannielle D. , Lowy Andrew M. , Tiriac Hervé
Published: September 2023

Table S3. Results of RPPA and transcriptomic analyses.
Table S1 from Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
Authors: Gulay Kevin Christian Montecillo , Zhang Xinlian , Pantazopoulou Vasiliki , Patel Jay , Esparza Edgar , Pran Babu Deepa Sheik , Ogawa Satoshi , Weitz Jonathan , Ng Isabella , Mose Evangeline S. , Pu Minya , Engle Dannielle D. , Lowy Andrew M. , Tiriac Hervé
Published: September 2023

Table S1. List of drugs used in this study.
Supplementary Data from Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
Authors: Gulay Kevin Christian Montecillo , Zhang Xinlian , Pantazopoulou Vasiliki , Patel Jay , Esparza Edgar , Pran Babu Deepa Sheik , Ogawa Satoshi , Weitz Jonathan , Ng Isabella , Mose Evangeline S. , Pu Minya , Engle Dannielle D. , Lowy Andrew M. , Tiriac Hervé
Published: September 2023

Supplemental Figure and Table Legends
Supplemental Figures from Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
Authors: Gulay Kevin Christian Montecillo , Zhang Xinlian , Pantazopoulou Vasiliki , Patel Jay , Esparza Edgar , Pran Babu Deepa Sheik , Ogawa Satoshi , Weitz Jonathan , Ng Isabella , Mose Evangeline S. , Pu Minya , Engle Dannielle D. , Lowy Andrew M. , Tiriac Hervé
Published: September 2023

Figure S1 - S12
Table S6 from CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Authors: Fattori Stéphane , Le Roy Aude , Houacine Jemila , Robert Lucie , Abes Riad , Gorvel Laurent , Granjeaud Samuel , Rouvière Marie-Sarah , Ben Amara Amira , Boucherit Nicolas , Tarpin Carole , Pakradouni Jihane , Charafe-Jauffret Emmanuelle , Houvenaeghel Gilles , Lambaudie Eric , Bertucci François , Rochigneux Philippe , Gonçalves Anthony , Foussat Arnaud , Chrétien Anne-Sophie , Olive Daniel
Published: September 2023

Mass cytometry panels, related to Figure 1
Table S3 from CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Authors: Fattori Stéphane , Le Roy Aude , Houacine Jemila , Robert Lucie , Abes Riad , Gorvel Laurent , Granjeaud Samuel , Rouvière Marie-Sarah , Ben Amara Amira , Boucherit Nicolas , Tarpin Carole , Pakradouni Jihane , Charafe-Jauffret Emmanuelle , Houvenaeghel Gilles , Lambaudie Eric , Bertucci François , Rochigneux Philippe , Gonçalves Anthony , Foussat Arnaud , Chrétien Anne-Sophie , Olive Daniel
Published: September 2023

cDC_monocyte_macrophage subpopulations gene features, related to Figure 1
Table S2 from CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Authors: Fattori Stéphane , Le Roy Aude , Houacine Jemila , Robert Lucie , Abes Riad , Gorvel Laurent , Granjeaud Samuel , Rouvière Marie-Sarah , Ben Amara Amira , Boucherit Nicolas , Tarpin Carole , Pakradouni Jihane , Charafe-Jauffret Emmanuelle , Houvenaeghel Gilles , Lambaudie Eric , Bertucci François , Rochigneux Philippe , Gonçalves Anthony , Foussat Arnaud , Chrétien Anne-Sophie , Olive Daniel
Published: September 2023

T cell and NK cell subpopulations gene features, related to Figure 1
Table S1 from CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Authors: Fattori Stéphane , Le Roy Aude , Houacine Jemila , Robert Lucie , Abes Riad , Gorvel Laurent , Granjeaud Samuel , Rouvière Marie-Sarah , Ben Amara Amira , Boucherit Nicolas , Tarpin Carole , Pakradouni Jihane , Charafe-Jauffret Emmanuelle , Houvenaeghel Gilles , Lambaudie Eric , Bertucci François , Rochigneux Philippe , Gonçalves Anthony , Foussat Arnaud , Chrétien Anne-Sophie , Olive Daniel
Published: September 2023

Clinical characteristics of patients with breast cancer
Supplementary_Materials_and_Methods_Figures_and_Figure_legends from CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Authors: Fattori Stéphane , Le Roy Aude , Houacine Jemila , Robert Lucie , Abes Riad , Gorvel Laurent , Granjeaud Samuel , Rouvière Marie-Sarah , Ben Amara Amira , Boucherit Nicolas , Tarpin Carole , Pakradouni Jihane , Charafe-Jauffret Emmanuelle , Houvenaeghel Gilles , Lambaudie Eric , Bertucci François , Rochigneux Philippe , Gonçalves Anthony , Foussat Arnaud , Chrétien Anne-Sophie , Olive Daniel
Published: September 2023

Supplementary_Materials_and_Methods_Figures_and_Figure_legends
Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis
Authors: Ghosh Santanu , Yang Rachel , Duraki Darjan , Zhu Junyao , Kim Ji Eun , Jabeen Musarrat , Mao Chengjian , Dai Xinyi , Livezey Mara R. , Boudreau Matthew W. , Park Ben H. , Nelson Erik R. , Hergenrother Paul J. , Shapiro David J.
Published: September 2023

Supplementary Movie 3
Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis
Authors: Ghosh Santanu , Yang Rachel , Duraki Darjan , Zhu Junyao , Kim Ji Eun , Jabeen Musarrat , Mao Chengjian , Dai Xinyi , Livezey Mara R. , Boudreau Matthew W. , Park Ben H. , Nelson Erik R. , Hergenrother Paul J. , Shapiro David J.
Published: September 2023

Supplementary Movie 4
Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis
Authors: Ghosh Santanu , Yang Rachel , Duraki Darjan , Zhu Junyao , Kim Ji Eun , Jabeen Musarrat , Mao Chengjian , Dai Xinyi , Livezey Mara R. , Boudreau Matthew W. , Park Ben H. , Nelson Erik R. , Hergenrother Paul J. , Shapiro David J.
Published: September 2023

Abstract
Several emerging therapies kill cancer cells primarily by inducing necrosis. As necrosis activates immune cells, potentially, uncovering the molecular drivers of anticancer therapy–induced necrosis could reveal approaches for enhancing immunotherapy efficacy. To identify necrosis-associated genes, we performed a genome-wide CRISPR-Cas9 screen with negative selection against necrosis-inducing preclinical agents BHPI and conducted follow-on experiments with ErSO. The screen identified transient receptor potential melastatin member 4 (TRPM4), a calcium-activated, ATP-inhibited, sodium-selective plasma membrane channel. Cancer cells selected for resistance to BHPI and ErSO exhibited robust TRPM4 downregulation, and TRPM4 reexpression restored sensitivity to ErSO. Notably, TRPM4 knockout (TKO) abolished ErSO-induced regression of breast tumors in mice. Supporting a broad role for TRPM4 in necrosis, knockout of TRPM4 reversed cell death induced by four additional diverse necrosis-inducing cancer therapies. ErSO induced anticipatory unfolded protein response (a-UPR) hyperactivation, long-term necrotic cell death, and release of damage-associated molecular patterns that activated macrophages and increased monocyte migration, all of which was abolished by TKO. Furthermore, loss of TRPM4 suppressed the ErSO-induced increase in cell volume and depletion of ATP. These data suggest that ErSO triggers initial activation of the a-UPR but that it is TRPM4-mediated sodium influx and cell swelling, resulting in osmotic stress, which sustains and propagates lethal a-UPR hyperactivation. Thus, TRPM4 plays a pivotal role in sustaining lethal a-UPR hyperactivation that mediates the anticancer activity of diverse necrosis-inducing therapies.
Significance:
A genome-wide CRISPR screen reveals a pivotal role for TRPM4 in cell death and immune activation following treatment with diverse necrosis-inducing anticancer therapies, which could facilitate development of necrosis-based cancer immunotherapies.
Supplementary Table S4 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
Authors: Mascarenhas John , Migliaccio Anna Rita , Kosiorek Heidi , Bhave Rupali , Palmer Jeanne , Kuykendall Andrew , Mesa Ruben , Rampal Raajit K. , Gerds Aaron T. , Yacoub Abdulraheem , Pettit Kristen , Talpaz Moshe , Komrokji Rami , Kremyanskaya Marina , Gonzalez Agapito , Fabris Frank , Johnson Kathryn , Dougherty Mikaela , McGovern Erin , Arango Ossa Juan , Domenico Dylan , Farnoud Noushin , Weinberg Rona Singer , Kong Amy , Najfeld Vesna , Vannucchi Alessandro Maria , Arciprete Francesca , Zingariello Maria , Falchi Mario , Salama Mohamed E. , Mead-Harvey Carolyn , Dueck Amylou , Varricchio Lilian , Hoffman Ronald
Published: September 2023

Individual patient data for AUC, Cmax and Tmax for dose levels 1 and 2 (lot A). Summary measures for DL 1 and DL2 are shown in red.
Supplementary Table S7 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Authors: Maron Steven B. , Chatila Walid , Walch Henry , Chou Joanne F. , Ceglia Nicholas , Ptashkin Ryan , Do Richard Kinh Gian , Paroder Viktoriya , Pandit-Taskar Neeta , Lewis Jason S. , Biachi De Castria Tiago , Sabwa Shalom , Socolow Fiona , Feder Lara , Thomas Jasmine , Schulze Isabell , Kim Kwanghee , Elzein Arijh , Bojilova Viktoria , Zatzman Matthew , Bhanot Umesh , Nagy Rebecca J. , Lee Jeeyun , Simmons Marc , Segal Michal , Ku Geoffrey Yuyat , Ilson David H. , Capanu Marinela , Hechtman Jaclyn F. , Merghoub Taha , Shah Sohrab , Schultz Nikolaus , Solit David B. , Janjigian Yelena Y.
Published: September 2023

Univariable Cox Proportional Hazard for PFS in HER2-targeted retrospective cohort.
Supplementary Figure S9 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
Authors: Mascarenhas John , Migliaccio Anna Rita , Kosiorek Heidi , Bhave Rupali , Palmer Jeanne , Kuykendall Andrew , Mesa Ruben , Rampal Raajit K. , Gerds Aaron T. , Yacoub Abdulraheem , Pettit Kristen , Talpaz Moshe , Komrokji Rami , Kremyanskaya Marina , Gonzalez Agapito , Fabris Frank , Johnson Kathryn , Dougherty Mikaela , McGovern Erin , Arango Ossa Juan , Domenico Dylan , Farnoud Noushin , Weinberg Rona Singer , Kong Amy , Najfeld Vesna , Vannucchi Alessandro Maria , Arciprete Francesca , Zingariello Maria , Falchi Mario , Salama Mohamed E. , Mead-Harvey Carolyn , Dueck Amylou , Varricchio Lilian , Hoffman Ronald
Published: September 2023

PK data for Cycle 1 (first 24 hours only) for A) 180 mg/m2 dose level and B) 550 mg/m2 dose level during dose escalation phase I.
Supplementary Figure S6 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
Authors: Mascarenhas John , Migliaccio Anna Rita , Kosiorek Heidi , Bhave Rupali , Palmer Jeanne , Kuykendall Andrew , Mesa Ruben , Rampal Raajit K. , Gerds Aaron T. , Yacoub Abdulraheem , Pettit Kristen , Talpaz Moshe , Komrokji Rami , Kremyanskaya Marina , Gonzalez Agapito , Fabris Frank , Johnson Kathryn , Dougherty Mikaela , McGovern Erin , Arango Ossa Juan , Domenico Dylan , Farnoud Noushin , Weinberg Rona Singer , Kong Amy , Najfeld Vesna , Vannucchi Alessandro Maria , Arciprete Francesca , Zingariello Maria , Falchi Mario , Salama Mohamed E. , Mead-Harvey Carolyn , Dueck Amylou , Varricchio Lilian , Hoffman Ronald
Published: September 2023

GATA1 expression in megakaryocytes from patients treated with AVID200
Supplementary Table S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Authors: Maron Steven B. , Chatila Walid , Walch Henry , Chou Joanne F. , Ceglia Nicholas , Ptashkin Ryan , Do Richard Kinh Gian , Paroder Viktoriya , Pandit-Taskar Neeta , Lewis Jason S. , Biachi De Castria Tiago , Sabwa Shalom , Socolow Fiona , Feder Lara , Thomas Jasmine , Schulze Isabell , Kim Kwanghee , Elzein Arijh , Bojilova Viktoria , Zatzman Matthew , Bhanot Umesh , Nagy Rebecca J. , Lee Jeeyun , Simmons Marc , Segal Michal , Ku Geoffrey Yuyat , Ilson David H. , Capanu Marinela , Hechtman Jaclyn F. , Merghoub Taha , Shah Sohrab , Schultz Nikolaus , Solit David B. , Janjigian Yelena Y.
Published: September 2023

Pembrolizumab/Trastuzumab/Chemotherapy Protocol Patient Demographics
Supplementary Figure S4 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
Authors: Mascarenhas John , Migliaccio Anna Rita , Kosiorek Heidi , Bhave Rupali , Palmer Jeanne , Kuykendall Andrew , Mesa Ruben , Rampal Raajit K. , Gerds Aaron T. , Yacoub Abdulraheem , Pettit Kristen , Talpaz Moshe , Komrokji Rami , Kremyanskaya Marina , Gonzalez Agapito , Fabris Frank , Johnson Kathryn , Dougherty Mikaela , McGovern Erin , Arango Ossa Juan , Domenico Dylan , Farnoud Noushin , Weinberg Rona Singer , Kong Amy , Najfeld Vesna , Vannucchi Alessandro Maria , Arciprete Francesca , Zingariello Maria , Falchi Mario , Salama Mohamed E. , Mead-Harvey Carolyn , Dueck Amylou , Varricchio Lilian , Hoffman Ronald
Published: September 2023

Oncoprint Analysis of Serial Samples from Phase 1b Trial of AVID200
Supplementary Figure S2 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
Authors: Mascarenhas John , Migliaccio Anna Rita , Kosiorek Heidi , Bhave Rupali , Palmer Jeanne , Kuykendall Andrew , Mesa Ruben , Rampal Raajit K. , Gerds Aaron T. , Yacoub Abdulraheem , Pettit Kristen , Talpaz Moshe , Komrokji Rami , Kremyanskaya Marina , Gonzalez Agapito , Fabris Frank , Johnson Kathryn , Dougherty Mikaela , McGovern Erin , Arango Ossa Juan , Domenico Dylan , Farnoud Noushin , Weinberg Rona Singer , Kong Amy , Najfeld Vesna , Vannucchi Alessandro Maria , Arciprete Francesca , Zingariello Maria , Falchi Mario , Salama Mohamed E. , Mead-Harvey Carolyn , Dueck Amylou , Varricchio Lilian , Hoffman Ronald
Published: September 2023

Baseline mutational profile of enrolled patients.
Supplementary Figure S1 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
Authors: Mascarenhas John , Migliaccio Anna Rita , Kosiorek Heidi , Bhave Rupali , Palmer Jeanne , Kuykendall Andrew , Mesa Ruben , Rampal Raajit K. , Gerds Aaron T. , Yacoub Abdulraheem , Pettit Kristen , Talpaz Moshe , Komrokji Rami , Kremyanskaya Marina , Gonzalez Agapito , Fabris Frank , Johnson Kathryn , Dougherty Mikaela , McGovern Erin , Arango Ossa Juan , Domenico Dylan , Farnoud Noushin , Weinberg Rona Singer , Kong Amy , Najfeld Vesna , Vannucchi Alessandro Maria , Arciprete Francesca , Zingariello Maria , Falchi Mario , Salama Mohamed E. , Mead-Harvey Carolyn , Dueck Amylou , Varricchio Lilian , Hoffman Ronald
Published: September 2023

MPN-RC 118 phase 1b study schema
Supplementary Figure S7 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Authors: Maron Steven B. , Chatila Walid , Walch Henry , Chou Joanne F. , Ceglia Nicholas , Ptashkin Ryan , Do Richard Kinh Gian , Paroder Viktoriya , Pandit-Taskar Neeta , Lewis Jason S. , Biachi De Castria Tiago , Sabwa Shalom , Socolow Fiona , Feder Lara , Thomas Jasmine , Schulze Isabell , Kim Kwanghee , Elzein Arijh , Bojilova Viktoria , Zatzman Matthew , Bhanot Umesh , Nagy Rebecca J. , Lee Jeeyun , Simmons Marc , Segal Michal , Ku Geoffrey Yuyat , Ilson David H. , Capanu Marinela , Hechtman Jaclyn F. , Merghoub Taha , Shah Sohrab , Schultz Nikolaus , Solit David B. , Janjigian Yelena Y.
Published: September 2023

Baseline biopsies from a patient demonstrating significant intra-patient heterogeneity with diffusely HER2+ and PD-L1– primary tumor and HER2– but PD-L1 CPS 100 retroperitoneal lymph node with neuroendocrine differentiation.
Supplementary Figure S3 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Authors: Maron Steven B. , Chatila Walid , Walch Henry , Chou Joanne F. , Ceglia Nicholas , Ptashkin Ryan , Do Richard Kinh Gian , Paroder Viktoriya , Pandit-Taskar Neeta , Lewis Jason S. , Biachi De Castria Tiago , Sabwa Shalom , Socolow Fiona , Feder Lara , Thomas Jasmine , Schulze Isabell , Kim Kwanghee , Elzein Arijh , Bojilova Viktoria , Zatzman Matthew , Bhanot Umesh , Nagy Rebecca J. , Lee Jeeyun , Simmons Marc , Segal Michal , Ku Geoffrey Yuyat , Ilson David H. , Capanu Marinela , Hechtman Jaclyn F. , Merghoub Taha , Shah Sohrab , Schultz Nikolaus , Solit David B. , Janjigian Yelena Y.
Published: September 2023

Response to pembrolizumab and trastuzumab induction according to pre-treatment 89Zr-trastuzumab PET avidity.
Supplementary Figure S2 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Authors: Maron Steven B. , Chatila Walid , Walch Henry , Chou Joanne F. , Ceglia Nicholas , Ptashkin Ryan , Do Richard Kinh Gian , Paroder Viktoriya , Pandit-Taskar Neeta , Lewis Jason S. , Biachi De Castria Tiago , Sabwa Shalom , Socolow Fiona , Feder Lara , Thomas Jasmine , Schulze Isabell , Kim Kwanghee , Elzein Arijh , Bojilova Viktoria , Zatzman Matthew , Bhanot Umesh , Nagy Rebecca J. , Lee Jeeyun , Simmons Marc , Segal Michal , Ku Geoffrey Yuyat , Ilson David H. , Capanu Marinela , Hechtman Jaclyn F. , Merghoub Taha , Shah Sohrab , Schultz Nikolaus , Solit David B. , Janjigian Yelena Y.
Published: September 2023

Survival and response in patients receiving trastuzumab/chemotherapy + PD-1 inhibition on- or off-protocol (n=66). a, Progression-free survival and objective response rate by cohort. b, Overall survival by cohort.
Supplementary Data S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Authors: Maron Steven B. , Chatila Walid , Walch Henry , Chou Joanne F. , Ceglia Nicholas , Ptashkin Ryan , Do Richard Kinh Gian , Paroder Viktoriya , Pandit-Taskar Neeta , Lewis Jason S. , Biachi De Castria Tiago , Sabwa Shalom , Socolow Fiona , Feder Lara , Thomas Jasmine , Schulze Isabell , Kim Kwanghee , Elzein Arijh , Bojilova Viktoria , Zatzman Matthew , Bhanot Umesh , Nagy Rebecca J. , Lee Jeeyun , Simmons Marc , Segal Michal , Ku Geoffrey Yuyat , Ilson David H. , Capanu Marinela , Hechtman Jaclyn F. , Merghoub Taha , Shah Sohrab , Schultz Nikolaus , Solit David B. , Janjigian Yelena Y.
Published: September 2023

Supplemental Data, Spreadsheet
Supplementary Data 2 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Authors: González-Muñoz Teresa , Di Giannatale Angela , García-Silva Susana , Santos Vanesa , Sánchez-Redondo Sara , Savini Claudia , Graña-Castro Osvaldo , Blanco-Aparicio Carmen , Fischer Suzanne , De Wever Olivier , Creus-Bachiller Edgar , Ortega-Bertran Sara , Pisapia David J. , Rodríguez-Peralto Jose L. , Fernández-Rodríguez Juana , Pérez-Portabella Cleofé Romagosa , Alaggio Rita , Benassi Maria Serena , Pazzaglia Laura , Scotlandi Katia , Ratner Nancy , Yohay Kaleb , Theuer Charles P. , Peinado Héctor
Published: September 2023

Significant deregulated genes in shENG versus shScramble STS26T cells.
Table S1 from A Novel HOXA10-Associated 5-Gene–Based Prognostic Signature for Stratification of Short-term Survivors of Pancreatic Ductal Adenocarcinoma
Authors: Kisling Sophia G. , Atri Pranita , Shah Ashu , Cox Jesse L. , Sharma Sunandini , Smith Lynette M. , Ghersi Dario , Batra Surinder K.
Published: September 2023

GSEA gene sets enriched in STS PDAC patients
Suppl. Figure 5 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Authors: González-Muñoz Teresa , Di Giannatale Angela , García-Silva Susana , Santos Vanesa , Sánchez-Redondo Sara , Savini Claudia , Graña-Castro Osvaldo , Blanco-Aparicio Carmen , Fischer Suzanne , De Wever Olivier , Creus-Bachiller Edgar , Ortega-Bertran Sara , Pisapia David J. , Rodríguez-Peralto Jose L. , Fernández-Rodríguez Juana , Pérez-Portabella Cleofé Romagosa , Alaggio Rita , Benassi Maria Serena , Pazzaglia Laura , Scotlandi Katia , Ratner Nancy , Yohay Kaleb , Theuer Charles P. , Peinado Héctor
Published: September 2023

Combined anti-ENG/anti-MEK therapy inhibits MPNST growth without toxicity in vivo.
Figure S3 from A Novel HOXA10-Associated 5-Gene–Based Prognostic Signature for Stratification of Short-term Survivors of Pancreatic Ductal Adenocarcinoma
Authors: Kisling Sophia G. , Atri Pranita , Shah Ashu , Cox Jesse L. , Sharma Sunandini , Smith Lynette M. , Ghersi Dario , Batra Surinder K.
Published: September 2023

CIBERSORT analysis for HOXA10 and its driven signature
Suppl. Figure 3 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Authors: González-Muñoz Teresa , Di Giannatale Angela , García-Silva Susana , Santos Vanesa , Sánchez-Redondo Sara , Savini Claudia , Graña-Castro Osvaldo , Blanco-Aparicio Carmen , Fischer Suzanne , De Wever Olivier , Creus-Bachiller Edgar , Ortega-Bertran Sara , Pisapia David J. , Rodríguez-Peralto Jose L. , Fernández-Rodríguez Juana , Pérez-Portabella Cleofé Romagosa , Alaggio Rita , Benassi Maria Serena , Pazzaglia Laura , Scotlandi Katia , Ratner Nancy , Yohay Kaleb , Theuer Charles P. , Peinado Héctor
Published: September 2023

ENG knockdown does not affect MPNST cell apoptosis in vivo.
Supplementary Figure S8 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Authors: Traphagen Nicole A. , Schwartz Gary N. , Tau Steven , Roberts Alyssa M. , Jiang Amanda , Hosford Sarah R. , Marotti Jonathan D. , Goen Abigail E. , Romo Bianca A. , Johnson Anneka L. , Duffy Emily-Claire K. , Demidenko Eugene , Heverly Paul , Mosesson Yaron , Soucy Shannon M. , Kolling Fred , Miller Todd W.
Published: September 2023

Supplementary Figure S8- Individual tumor volumes from mice treated ± E2.
Supplementary Figure S6 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Authors: Traphagen Nicole A. , Schwartz Gary N. , Tau Steven , Roberts Alyssa M. , Jiang Amanda , Hosford Sarah R. , Marotti Jonathan D. , Goen Abigail E. , Romo Bianca A. , Johnson Anneka L. , Duffy Emily-Claire K. , Demidenko Eugene , Heverly Paul , Mosesson Yaron , Soucy Shannon M. , Kolling Fred , Miller Todd W.
Published: September 2023

Histology of baseline human tumors.
Supplementary Figure S5 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Authors: Traphagen Nicole A. , Schwartz Gary N. , Tau Steven , Roberts Alyssa M. , Jiang Amanda , Hosford Sarah R. , Marotti Jonathan D. , Goen Abigail E. , Romo Bianca A. , Johnson Anneka L. , Duffy Emily-Claire K. , Demidenko Eugene , Heverly Paul , Mosesson Yaron , Soucy Shannon M. , Kolling Fred , Miller Todd W.
Published: September 2023

Supplementary Figure S5- ER-negative BT-20 cells do not exhibit increased DNA damage upon E2 treatment, while MCF-7/LTED show weak response.
Supplementary Figure S10 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Authors: Traphagen Nicole A. , Schwartz Gary N. , Tau Steven , Roberts Alyssa M. , Jiang Amanda , Hosford Sarah R. , Marotti Jonathan D. , Goen Abigail E. , Romo Bianca A. , Johnson Anneka L. , Duffy Emily-Claire K. , Demidenko Eugene , Heverly Paul , Mosesson Yaron , Soucy Shannon M. , Kolling Fred , Miller Todd W.
Published: September 2023

Supplementary Figure S10- Representative IHC images from WHIM16 and CTG-3346 tumors.
Supplementary Table S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Authors: Abel Melissa L. , Takahashi Nobuyuki , Peer Cody , Redon Christophe E. , Nichols Samantha , Vilimas Rasa , Lee Min-Jung , Lee Sunmin , Shelat Meenakshi , Kattappuram Robbie , Sciuto Linda , Pinkiert Danielle , Graham Chante , Butcher Donna , Karim Baktiar , Sharma Ajit Kumar , Malin Justin , Kumar Rajesh , Schultz Christopher W. , Goyal Shubhank , del Rivero Jaydira , Krishnamurthy Manan , Upadhyay Deep , Schroeder Brett , Sissung Tristan , Tyagi Manoj , Kim Jung , Pommier Yves , Aladjem Mirit , Raffeld Mark , Figg William Douglas , Trepel Jane , Xi Liqiang , Desai Parth , Thomas Anish
Published: September 2023

Study Representativeness
Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Authors: Abel Melissa L. , Takahashi Nobuyuki , Peer Cody , Redon Christophe E. , Nichols Samantha , Vilimas Rasa , Lee Min-Jung , Lee Sunmin , Shelat Meenakshi , Kattappuram Robbie , Sciuto Linda , Pinkiert Danielle , Graham Chante , Butcher Donna , Karim Baktiar , Sharma Ajit Kumar , Malin Justin , Kumar Rajesh , Schultz Christopher W. , Goyal Shubhank , del Rivero Jaydira , Krishnamurthy Manan , Upadhyay Deep , Schroeder Brett , Sissung Tristan , Tyagi Manoj , Kim Jung , Pommier Yves , Aladjem Mirit , Raffeld Mark , Figg William Douglas , Trepel Jane , Xi Liqiang , Desai Parth , Thomas Anish
Published: September 2023

Comparison of treatment-related adverse events with the combination of berzosertib and topotecan
Supplementary Figure S3 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Authors: Abel Melissa L. , Takahashi Nobuyuki , Peer Cody , Redon Christophe E. , Nichols Samantha , Vilimas Rasa , Lee Min-Jung , Lee Sunmin , Shelat Meenakshi , Kattappuram Robbie , Sciuto Linda , Pinkiert Danielle , Graham Chante , Butcher Donna , Karim Baktiar , Sharma Ajit Kumar , Malin Justin , Kumar Rajesh , Schultz Christopher W. , Goyal Shubhank , del Rivero Jaydira , Krishnamurthy Manan , Upadhyay Deep , Schroeder Brett , Sissung Tristan , Tyagi Manoj , Kim Jung , Pommier Yves , Aladjem Mirit , Raffeld Mark , Figg William Douglas , Trepel Jane , Xi Liqiang , Desai Parth , Thomas Anish
Published: September 2023

PK results vs toxicity
Supplementary Table S7 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
Authors: Cornwell Abigail C. , Tisdale Arwen A. , Venkat Swati , Maraszek Kathryn E. , Alahmari Abdulrahman A. , George Anthony , Attwood Kristopher , George Madison , Rempinski Donald , Franco-Barraza Janusz , Seshadri Mukund , Parker Mark D. , Cortes Gomez Eduardo , Fountzilas Christos , Cukierman Edna , Steele Nina G. , Feigin Michael E.
Published: September 2023

Supplementary Table S7. Breast cancer patient characteristics, median survival, and Multivariate Cox Regression Modeling
Supplementary Table S14 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
Authors: Cornwell Abigail C. , Tisdale Arwen A. , Venkat Swati , Maraszek Kathryn E. , Alahmari Abdulrahman A. , George Anthony , Attwood Kristopher , George Madison , Rempinski Donald , Franco-Barraza Janusz , Seshadri Mukund , Parker Mark D. , Cortes Gomez Eduardo , Fountzilas Christos , Cukierman Edna , Steele Nina G. , Feigin Michael E.
Published: September 2023

Supplementary Table S14. Prostate cancer patient characteristics, median survival, and Multivariate Cox Regression Modeling
Supplementary Table S11 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
Authors: Cornwell Abigail C. , Tisdale Arwen A. , Venkat Swati , Maraszek Kathryn E. , Alahmari Abdulrahman A. , George Anthony , Attwood Kristopher , George Madison , Rempinski Donald , Franco-Barraza Janusz , Seshadri Mukund , Parker Mark D. , Cortes Gomez Eduardo , Fountzilas Christos , Cukierman Edna , Steele Nina G. , Feigin Michael E.
Published: September 2023

Supplementary Table S11. Renal cancer patient characteristics, median survival, and Multivariate Cox Regression Modeling.
Supplementary Figure S3 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
Authors: Cornwell Abigail C. , Tisdale Arwen A. , Venkat Swati , Maraszek Kathryn E. , Alahmari Abdulrahman A. , George Anthony , Attwood Kristopher , George Madison , Rempinski Donald , Franco-Barraza Janusz , Seshadri Mukund , Parker Mark D. , Cortes Gomez Eduardo , Fountzilas Christos , Cukierman Edna , Steele Nina G. , Feigin Michael E.
Published: September 2023

Supplementary Figure S3. LOR treatment promotes IL-6 expression in authochthonous KPC CAFs in vivo
Supplementary Figure S3 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
Authors: Tovey Holly , Sipos Orsolya , Parker Joel S. , Hoadley Katherine A. , Quist Jelmar , Kernaghan Sarah , Kilburn Lucy , Salgado Roberto , Loi Sherene , Kennedy Richard D. , Roxanis Ioannis , Gazinska Patrycja , Pinder Sarah E. , Bliss Judith , Perou Charles M. , Haider Syed , Grigoriadis Anita , Tutt Andrew , Cheang Maggie Chon U.
Published: September 2023

Heatmap of signatures used for clustering by the resulting novel clusters.
Figure 5 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
Authors: Tovey Holly , Sipos Orsolya , Parker Joel S. , Hoadley Katherine A. , Quist Jelmar , Kernaghan Sarah , Kilburn Lucy , Salgado Roberto , Loi Sherene , Kennedy Richard D. , Roxanis Ioannis , Gazinska Patrycja , Pinder Sarah E. , Bliss Judith , Perou Charles M. , Haider Syed , Grigoriadis Anita , Tutt Andrew , Cheang Maggie Chon U.
Published: September 2023

Results of a novel clustering. A, Response rates by novel clusters and treatment groups. P values are presented from Fisher exact tests. Clusters 4 and 6 are not shown due to small numbers. B, Heatmap showing biological features of each novel cluster. PGA, percentage of genome altered; SI, Shannon diversity index; NtAI, number of telomeric allelic imbalances; AiCna, allelic imbalanced CNA; AbCna, allelic balanced CNA; CnLOH, copy number neutral loss of heterozygosity.
Figure 4 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
Authors: Tovey Holly , Sipos Orsolya , Parker Joel S. , Hoadley Katherine A. , Quist Jelmar , Kernaghan Sarah , Kilburn Lucy , Salgado Roberto , Loi Sherene , Kennedy Richard D. , Roxanis Ioannis , Gazinska Patrycja , Pinder Sarah E. , Bliss Judith , Perou Charles M. , Haider Syed , Grigoriadis Anita , Tutt Andrew , Cheang Maggie Chon U.
Published: September 2023

Association of biomarkers of interest with clinical outcomes by treatment group in chemotherapy-naïve patients. A, Changes in transcriptional DDR features between primary and recurrent disease. P values presented from t tests comparing primary and recurrent scores in paired samples. PT, primary tumor; REC, recurrent tumor. B, Association of biomarkers with objective response in chemotherapy-naïve patients. Odds ratios for each biomarker are presented from univariable logistic regression models. Stars indicate that an odds ratio could not be estimated due to colinearity (i.e., a cutoff could perfectly separate responders from nonresponders). C, Biomarker by response in chemotherapy-naïve, carboplatin-treated patients for biomarkers where a model could not be fitted due to a perfect cutoff between responders and nonresponders. D, Association of biomarkers with PFS in chemotherapy-naïve patients. Model coefficients of each biomarker are presented from linear regression of restricted mean PFS. Ninety-five percent confidence intervals are shown.
Supplemental Figure 2 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Authors: Gallois Claire , Landi Matteo , Taieb Julien , Sroussi Marine , Saberzadeh-Ardestani Bahar , Cazelles Antoine , Lonardi Sara , Bergamo Francesca , Intini Rossana , Maddalena Giulia , Pietrantonio Filippo , Corti Francesca , Ambrosini Margherita , Martinetti Antonia , Germani Marco Maria , Boccaccio Chiara , Vetere Guglielmo , Mouillet-Richard Sophie , de Reynies Aurélien , Sinicrope Frank A. , Cremolini Chiara , Laurent-Puig Pierre
Published: September 2023

Kaplan Meier curves for progression-free survival according to the unsupervised clusters and the line of immune checkpoint inhibitor